|
1
|
Tinhofer I, Bernhard D, Senfter M, Anether
G, Loeffler M, Kroemer G, Kofler R, Csordas A and Greil R:
Resveratrol, a tumor-suppressive compound from grapes, induces
apoptosis via a novel mitochondrial pathway controlled by Bcl-2.
FASEB J. 15:1613–1615. 2001.PubMed/NCBI
|
|
2
|
Ding J, Zai X and Tang Z: Effects of
resveratrol on fibroblasts of pathological scar and its
Tgf-β1/smads signaling pathway. J Hebei Med Univ. 35:37–41.
2014.(In Chinese).
|
|
3
|
Huang LP, Mao Z, Zhang L, Liu XX, Huang C
and Jia ZS: Screening of differentially expressed genes in
pathological scar tissues using expression microarray. Genet Mol
Res. 14:10743–10751. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Teofoli P, Barduagni S, Ribuffo M,
Campanella A, De Pita' O and Puddu P: Expression of Bcl-2, p53,
c-jun and c-fos protooncogenes in keloids and hypertrophic scars. J
Dermatol Sci. 22:31–37. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Steelman LS, Chappell WH, Abrams SL, Kempf
RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F,
Mazzarino MC, et al: Roles of the Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity
to therapy-implications for cancer and aging. Aging (Albany NY).
3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van der Veer WM, Bloemen MC, Ulrich MM,
Molema G, van Zuijlen PP, Middelkoop E and Niessen FB: Potential
cellular and molecular causes of hypertrophic scar formation.
Burns. 35:15–29. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bollero D, Malvasio V, Catalano F and
Stella M: Negative pressure surgical management after pathological
scar surgical excision: a first report. Int Wound J. 12:17–21.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang C and Ogawa R: The link between
hypertension and pathological scarring: does hypertension cause or
promote keloid and hypertrophic scar pathogenesis? Wound Repair
Regen. 22:462–466. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhai XX, Ding JC and Tang ZM: Resveratrol
inhibits proliferation and induces apoptosis of pathological scar
fibroblasts through the mechanism involving TGF-β1/Smads signaling
pathway. Cell Biochem Biophys. 71:1267–1272. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Susami T: Wound healing in the palatal
mucosa and the mechanism of scar formation. Kokubyo Gakkai Zasshi.
52:5961985.(In Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu SL: Mechanism of scar formation and
strategy of treatment. Zhonghua Shao Shang Za Zhi. 29:130–133.
2013.(In Chinese). PubMed/NCBI
|
|
12
|
Sun Q, Guo S, Wang CC, Sun X, Wang D, Xu
N, Jin SF and Li KZ: Cross-talk between TGF-β/Smad pathway and
Wnt/β-catenin pathway in pathological scar formation. Int J Clin
Exp Pathol. 8:7631–7639. 2015.PubMed/NCBI
|
|
13
|
Chen W, Fu X, Sun T, Sun X, Zhao Z and
Sheng Z: Change of gene expression of transforming growth
factor-beta1, Smad 2 and Smad 3 in hypertrophic scars skins.
Zhonghua Wai Ke Za Zhi. 40:17–19. 2002.(In Chinese). PubMed/NCBI
|
|
14
|
Brown KA, Pietenpol JA and Moses HL: A
tale of two proteins: differential roles and regulation of Smad2
and Smad3 in TGF-beta signaling. J Cell Biochem. 101:9–33. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu R and Cen Y: Transforming growth factor
beta1/Smad3 signal transduction pathway and post-traumatic scar
formation. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 26:330–335.
2012.(In Chinese). PubMed/NCBI
|
|
16
|
Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ,
Gao FH, Xu MH, Chen GQ, Han ZG and Fang JY: mTOR signaling pathway
is a target for the treatment of colorectal cancer. Ann Surg Oncol.
16:2617–2628. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Laplante M and Sabatini DM: mTOR signaling
in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Petroulakis E, Mamane Y, Le Bacquer O,
Shahbazian D and Sonenberg N: mTOR signaling: implications for
cancer and anticancer therapy. Br J Cancer. 96:(Suppl). R11–R15.
2007.PubMed/NCBI
|
|
19
|
Shinojima N, Yokoyama T, Kondo Y and Kondo
S: Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in
curcumin-induced autophagy. Autophagy. 3:635–637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heinonen H, Nieminen A, Saarela M,
Kallioniemi A, Klefström J, Hautaniemi S and Monni O: Deciphering
downstream gene targets of PI3K/mTOR/p70S6K pathway in breast
cancer. BMC Genomics. 9:3482008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hou G, Xue L, Lu Z, Fan T, Tian F and Xue
Y: An activated mTOR/p70S6K signaling pathway in esophageal
squamous cell carcinoma cell lines and inhibition of the pathway by
rapamycin and siRNA against mTOR. Cancer Lett. 253:236–248. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao KS: Biological characteristics and
effects of resveratrol. Chinese Journal of Pathophysiology.
28:1709–1711. 2012.(In Chinese).
|
|
23
|
Pangeni R, Sahni JK, Ali J, Sharma S and
Baboota S: Resveratrol: review on therapeutic potential and recent
advances in drug delivery. Expert Opin Drug Deliv. 11:1285–1298.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu JM, Hsieh TC and Wang Z:
Cardioprotection by resveratrol: a review of effects/targets in
cultured cells and animal tissues. Am J Cardiovasc Dis. 1:38–47.
2011.PubMed/NCBI
|
|
25
|
Athar M, Back JH, Tang X, Kim KH,
Kopelovich L, Bickers DR and Kim AL: Resveratrol: a review of
preclinical studies for human cancer prevention. Toxicol Appl
Pharmacol. 224:274–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
